User login
Article Type
Changed
Tue, 05/21/2019 - 12:13
Display Headline
Optimal Duration of Antiplatelet Therapy Following Acute Coronary Syndrome
Sponsor
Funding for this newsletter series was provided by AstraZeneca.
Issue
The Journal of Family Practice - 66(12)
Publications
Sections
Sponsor
Funding for this newsletter series was provided by AstraZeneca.
Sponsor
Funding for this newsletter series was provided by AstraZeneca.
Issue
The Journal of Family Practice - 66(12)
Issue
The Journal of Family Practice - 66(12)
Publications
Publications
Article Type
Display Headline
Optimal Duration of Antiplatelet Therapy Following Acute Coronary Syndrome
Display Headline
Optimal Duration of Antiplatelet Therapy Following Acute Coronary Syndrome
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Consolidated Pubs: Do Not Show Source Publication Logo
Use ProPublica